CD47 and myelodysplastic syndrome: The results showed that magrolimab combined with azacitidine in patients with myelodysplastic syndrome (MDS) reached an overall response rate of 92%.466 In addition, another clinical study showed that magrolimab combined with rituximab resulted in an overall response rate of 90% in lymphoma patients.467 These results have led to many additional drug candidates targeting the CD47/SIRPα pathway, such as TTI-621/622, ALX148, and OSE-172 (Table 3).